Our data show that autophagy induction improves clinical outcomes in lymphoma patients, suggesting that autophagy modulation may be a crucial target in overcoming acquired resistance and improving the clinical outcomes of patients undergoing R-CHOP therapy (Figure 9). Here, DDIT3 is linked to lymphoma.